IN THE NEWS

NEWS RELEASE CYTOAGENTS RECEIVES NIH FUNDING TO ACCELERATE TREATMENT FOR CYTOKINE STORM 

Pittsburgh May 13, 2020

CytoAgents, a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases, announced today that it has been awarded a National Institutes of Health (NIH) grant to accelerate the development of its lead drug candidate, GP1681, an investigational new drug to treat severe influenza, and potentially COVID-19, by targeting hypercytokinemia, more commonly known as “cytokine storm.” Read More

NEWS RELEASE QUOTIENT SCIENCES AND CYTOAGENTS ACCELERATE POTENTIAL TREATMENT FOR COVID-19 CYTOKINE STORM

Nottingham, U.K., and Pittsburgh April 28, 2020

A collaboration to accelerate the development of a lead COVID-19 drug candidate into human clinical trials was announced today by Quotient Sciences, a leading provider of innovative drug development and manufacturing solutions, and CytoAgents, Inc., a privately held biotechnology company focused on the development of pharmaceutical products for the treatment of viral infectious diseases. Read More

© 2020 by CytoAgents

  • LI-In-Bug